Patents by Inventor Joel M. Linden

Joel M. Linden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
    Patent number: 7396825
    Abstract: The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: July 8, 2008
    Assignee: University of Virginia Patent Foundation
    Inventors: Mark D. Okusa, Joel M. Linden, Timothy L. Macdonald, Alaa S. Awad
  • Method to reduce an inflammatory response from arthritis
    Patent number: 7378400
    Abstract: The present invention provides a therapeutic method for treating an inflammatory response caused by autoimmune stimulation, comprising the administration to a patient in need thereof of an antiinflammatory amount amount of an A2A adenosine receptor agonist. The autoimmune stimulation can be caused by arthritis, particularly rheumatoid arthritis. Optionally, the method includes administration of a type IV PDE inhibitor.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: May 27, 2008
    Assignee: University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Donald L. Kimpel, Joel M. Linden, Gail W. Sullivan
  • Pharmaceutical compositions having Aadenosine receptor agonist activity
    Patent number: 7226913
    Abstract: The present invention provides compositions for oral administration of compounds having A2A adenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: June 5, 2007
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Gail W. Sullivan, Ian J. Sarembock, Timothy MacDonald, Mark Okusa, Irving L. Kron, W. Michael Scheld
  • 2-propynyl adenosine analogs having Aagonist activity and compositions thereof
    Patent number: 7214665
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: May 8, 2007
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren Jean Murphree, Robert Alan Figler
  • 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Patent number: 7019027
    Abstract: The present invention relates to a compound of formula (I): wherein: R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and R4 and R5 taken together form a ring having from 5 to 10 carbon atoms. Additionally, the invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal subject, such as a human, wherein increased angiogenesis is desired, comprising administering to a mammal in need of such therapy an effective amount of the aforementioned thiophene selective adenosine A1 allosteric enhancer.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: March 28, 2006
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • 2-Amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Publication number: 20040180948
    Abstract: The present invention relates to a compound of formula (I): 1
    Type: Application
    Filed: March 23, 2004
    Publication date: September 16, 2004
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Patent number: 6713638
    Abstract: The present invention relates to a compound of formula (I): wherein: R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and R4 and R5 taken together form a ring having from 5 to 10 carbon atoms. Additionally, the invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal subject, such as a human, wherein increased angiogenesis is desired, comprising administering to a mammal in need of such therapy an effective amount of the aforementioned thiophene selective adenosine A1 allosteric enhancer.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: March 30, 2004
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • Method and compositions for treating the inflammatory response
    Patent number: 6670334
    Abstract: Agonists of A2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the inhibition of an inflammatory response in mammalian tissue, in vivo or in vitro.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: December 30, 2003
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Jayson M. Rieger, Gail W. Sullivan, Timothy L. Macdonald
  • 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
    Publication number: 20030186926
    Abstract: The invention provides compounds having the following general formula (I): 1
    Type: Application
    Filed: October 1, 2002
    Publication date: October 2, 2003
    Inventors: Joel M. Linden, Jayson M. Rieger, Timothy L. MacDonald, Gail W. Sullivan, Lauren Jean Murphree, Robert Alan Figler
  • Methods and compositions for treating inflammatory response
    Publication number: 20030162742
    Abstract: Compositions for oral administration of compounds having A2A adenosine receptor antagonist activity are provided. These compositions are useful for treatment of inflammatory conditions.
    Type: Application
    Filed: March 3, 2003
    Publication date: August 28, 2003
    Applicant: University of Virginia Patent Foundation, University of Virginia.
    Inventors: Joel M. Linden, Gail W. Sullivan, Ian J. Sarembock, Timothy MacDonald, Mark Okusa, Irving L. Kron, W. Michael Scheld
  • 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Publication number: 20030078248
    Abstract: The present invention relates to a compound of formula (I): 1
    Type: Application
    Filed: May 20, 2002
    Publication date: April 24, 2003
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
    Patent number: 6545002
    Abstract: The present invention provides compounds having the formula I: X is (C1-C8)alkylene, (C2-C8)alkenylene, (C2-C8)alkynylene, wherein one of the carbon atoms in the alkylene, alkenylene or alkynylene groups is optionally replaced with a group having the formula —O—, —N(R4)C(O)—, —OC(O—, S—, —S(O)—or —SO2—, or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising compounds having the formula I. The compounds of the invention are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents for treatment of diseases that are mediated by A2B adenosine receptors.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: April 8, 2003
    Assignees: University of Virginia Patent Foundation, National Institutes of Health
    Inventors: Joel M. Linden, Kenneth A. Jacobson, Yong-Chul Kim
  • Methods and compositions for treating inflammatory response
    Patent number: 6531457
    Abstract: Compounds and methods are provided to treat inflammatory conditions with certain A2A adenosine receptor antagonists.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: March 11, 2003
    Assignees: University of Virginia, University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Gail W. Sullivan, Ian J. Sarembock, Timothy MacDonald, Mark Okusa, Irving L. Kron, W. Michael Scheld
  • Method compositions for treating the inflammatory response
    Patent number: 6514949
    Abstract: Agonists of A2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: February 4, 2003
    Assignees: University of Virginia Patent Foundation, University of Virginia
    Inventors: Joel M. Linden, Gail W. Sullivan, W. Michael Scheld
  • Method for treating restenosis with A2A adenosine receptor agonists
    Patent number: 6448235
    Abstract: Agonists of A2A adenosine receptors in combination with rolipram, its derivatives or other Type IV phosphodiesterase (PDE) inhibitors are effective for the treatment of restenosis.
    Type: Grant
    Filed: April 4, 2000
    Date of Patent: September 10, 2002
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Gail W. Sullivan, Ian Sarembock, W. Michael Sheld
  • Method and compositions for treating the inflammatory response
    Publication number: 20020111327
    Abstract: Agonists of A2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the inhibition of an inflammatory response in mammalian tissue, in vivo or in vitro.
    Type: Application
    Filed: January 7, 2002
    Publication date: August 15, 2002
    Inventors: Joel M. Linden, Jayson M. Rieger, Gail W. Sullivan, Timothy L. MacDonald
  • METHOD FOR TREATING RESTENOSIS WITH A2A ADENOSINE RECEPTOR AGONISTS
    Publication number: 20020082240
    Abstract: Agonists of A2A adenosine receptors in combination with rolipram, its derivatives or other Type IV phosphodiesterase (PDE) inhibitors are effective for the treatment of inflammatory diseases.
    Type: Application
    Filed: April 4, 2000
    Publication date: June 27, 2002
    Inventors: Joel M Linden, Gail W Sullivan, Ian Sarembock, W Michael Sheld
  • Induction of pharmacological stress with adenosine receptor agonists
    Patent number: 6322771
    Abstract: A method is provided employing A2A adenosine receptor agonists as vasodilators to detect the presence and assess the severity of coronary artery stenosis.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: November 27, 2001
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, David K. Glover, George A. Beller, Timothy MacDonald
  • Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
    Patent number: 6303619
    Abstract: The invention concerns the use of a xanthine or a xanthine derivative having a meta-substituted acidic aryl at the 8-position to specifically modulate the physiologic role of adenosine activation of its various receptors.
    Type: Grant
    Filed: March 12, 1998
    Date of Patent: October 16, 2001
    Assignees: University of Virginia, University of Virginia Patent Foundation
    Inventor: Joel M. Linden
  • Methods and compositions for treating inflammatory response
    Publication number: 20010027185
    Abstract: Compounds and methods are provided to treat inflammatory conditions with certain A2A adenosine receptor antagonists.
    Type: Application
    Filed: April 5, 2001
    Publication date: October 4, 2001
    Applicant: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Gail W. Sullivan, Ian J. Sarembock, Timothy MacDonald, Mark Okusa, Irving L. Kron, W. Michael Scheld